Why is Novartis India falling/rising?

Recent Price Movement and Market Comparison

Novartis India’s shares have been on a downward trajectory, falling 1.79% over the past week compared to a more modest 0.53% decline in the Sensex. The trend extends over longer periods, with the stock losing 7.10% in the last month while the Sensex gained 2.16%. Year-to-date, the stock is down 13.34%, contrasting sharply with the Sensex’s 9.12% rise. Over the last year, the stock has plummeted 24.60%, whereas the benchmark index has appreciated by 5.32%. This underperformance is also evident over three and five-year horizons, where Novartis India’s returns lag significantly behind the broader market.

On the day in question, the stock underperformed its sector by 1.77%, marking the third consecutive day of declines and touching an intraday low of ₹790, a 2.36% drop from the previous close. The share price is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained bearish sentiment among investors.

Fundamental Factors and Valuation

Despite the negative price action, Novartis India maintains some positive fundamental attributes. The company boasts a low debt-to-equity ratio, effectively zero, which reduces financial risk. Its return on equity (ROE) stands at a respectable 13.8%, and the stock trades at a price-to-book value of 2.5, indicating a fair valuation relative to historical peer averages. Furthermore, the company’s profits have increased by 22% over the past year, a notable achievement given the stock’s 24.60% decline in the same period. The price/earnings to growth (PEG) ratio of 0.8 suggests the stock may be undervalued relative to its earnings growth potential.

Additionally, the stock offers a dividend yield of 3.09%, which is attractive for income-focused investors. Liquidity remains adequate, with trading volumes sufficient to support moderate trade sizes without significant price impact. Investor participation has also seen a rise, with delivery volumes on 25 Oct increasing by over 230% compared to the five-day average, indicating some renewed interest in the shares.

Challenges Weighing on the Stock

However, several factors contribute to the ongoing weakness in Novartis India’s share price. The company reported flat financial results in September 2025, which failed to inspire confidence among investors. A particularly concerning metric is the debtors turnover ratio, which at 0.73 times is the lowest among its peers, signalling potential inefficiencies in receivables management and cash flow challenges.

Moreover, domestic mutual funds hold a negligible stake of just 0.01% in the company. Given their capacity for detailed research and due diligence, this minimal exposure may reflect a lack of conviction in the stock’s prospects or valuation at current levels. The stock’s underperformance relative to the BSE500 index over the past three years, one year, and three months further underscores its struggles to deliver competitive returns.

Outlook and Investor Considerations

In summary, Novartis India’s recent share price decline is driven by a combination of underwhelming financial results, weak relative performance against benchmarks, and cautious investor sentiment. While the company’s fundamentals such as low leverage, decent ROE, and profit growth provide some support, the flat quarterly results and poor receivables turnover ratio raise concerns about operational efficiency and growth sustainability.

Investors should weigh these factors carefully, considering the stock’s persistent underperformance over multiple time frames and the limited endorsement from domestic institutional investors. The current valuation appears fair but not compelling enough to offset the risks highlighted by recent financial metrics and market behaviour.

Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →